Lexeo completes Mantle Therapeutics acquisition for $5.3 million cash plus stock
Lexeo Therapeutics completed its merger with Mantle Therapeutics, under a merger agreement dated September 16, 2026. Mantle shareholders received $5.3 million in cash, subject to adjustments, and $3 million in Lexeo common stock, and the stock was issued without SEC registration. Additional contingent payments of $1 million in cash and up to $12 million in milestone payments may never become payable.
Key points
- Upfront consideration: $5.3 million in cash, subject to certain adjustments, plus $3 million in Lexeo common stock
- Lexeo common stock issued in the merger was not registered and relied on Section 4(a)(2) and/or Regulation D exemptions
- Contingent payments: a one-time $1 million cash payment and up to $12 million in development and regulatory milestone payments over a 12-year term
- Merger agreement dated September 16, 2026, among Lexeo, Mantle Therapeutics Inc., Magma Merger Sub Inc. and Shareholder Representative Services LLC
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.